Long COVID Trial, Recruiting (NCT07295483)

Long COVID Trial, Recruiting NCT07295483 Sponsor: Instituto de Investigación Biomédica de Salamanca Condition: Long COVID

Printed from Voxsanity (voxsanity.com.au) — NCT07295483 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Long Covid

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years old or older.
You must have previously had a confirmed COVID-19 infection.
You must have been diagnosed with long COVID based on the World Health Organization's definition.
You must have already taken part in the baseline BioICOPER study.
You must be willing to sign a consent form agreeing to be re-evaluated for this study.

Who may not be able to join:

You may not be able to join if you currently have an acute (sudden or severe) illness that would prevent you from taking part.
You may not be able to join if a cognitive (thinking or memory) or physical difficulty would make it too hard to take part in data collection (confirm with trial site).
You may not be able to join if you have withdrawn or taken back a previously signed consent form.
You may not be able to join if you are under 18 years old.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Manuel Angel Gomez Marcos, MD, PhD, Centro Asistencial Universitario de Salamanca (CAUSA)

Phone: +346751143551

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07295483

Sponsor: Instituto de Investigación Biomédica de Salamanca

Phase: Not Applicable

Status: Recruiting

Condition: Long COVID

Trial contact: +346751143551

More information: https://clinicaltrials.gov/study/NCT07295483

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years old or older.
You must have previously had a confirmed COVID-19 infection.
You must have been diagnosed with long COVID based on the World Health Organization's definition.
You must have already taken part in the baseline BioICOPER study.
You must be willing to sign a consent form agreeing to be re-evaluated for this study.

Who may not be able to join:

You may not be able to join if you currently have an acute (sudden or severe) illness that would prevent you from taking part.
You may not be able to join if a cognitive (thinking or memory) or physical difficulty would make it too hard to take part in data collection (confirm with trial site).
You may not be able to join if you have withdrawn or taken back a previously signed consent form.
You may not be able to join if you are under 18 years old.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Instituto de Investigación Biomédica de Salamanca

Registry

ClinicalTrials.gov

Start date

9 February 2026

Est. completion

1 March 2029

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Progression of vascular stiffness measured by carotid-femoral pulse wave velocity (cfPWV)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov